Lumen Bioscience patents spirulina genetic engineering

Lumen Bioscience, a Seattle biotechnology company focused on orally delivered antibody therapeutics and other biologics, has announced that the U.S. Patent and Trademark Office has issued the company Patent No. 10,131,870, entitled “Targeted Mutagenesis in Spirulina”… [Read the full story]

Dr. Craig Behnke joins Lumen Bioscience as SVP

Lumen Bioscience, a Seattle company developing novel biologics on its proprietary spirulina expression platform, has announced that Dr. Craig Behnke has joined its executive team as Senior Vice President, Production and Development. Dr. Behnke will assume leadership of Lumen’s existing… [Read the full story]

Lumen raises $13M for spirulina extract

Seattle, WA-based Lumen Bioscience, a synthetic biotechnology company developing a novel bio-based product development platform, has raised $13 million of new capital, including a Series A investment round totaling $11.2M and a $1.8M grant from the US Department of Energy. The financing was led by Avista…